Evaluating zipalertinib with chemotherapy for advanced lung cancer
Official title: Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Run by Taiho Oncology, Inc. · NCT05973773 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if adding a new drug called zipalertinib to standard chemotherapy can help people with advanced lung cancer that has specific genetic mutations feel better and live longer.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 272 (estimated) |
| Sponsor | Taiho Oncology, Inc. Industry-sponsored |
| Drugs / interventions | amivantamab, gefitinib, erlotinib, afatinib, dacomitinib, osimertinib, mobocertinib, sunvozertinib, furmonertinib, poziotinib, Zipalertinib, radiation, chemotherapy |
| Locations | 114 sites (Henderson, Nevada and 113 other locations) |
| Trial ID | NCT05973773 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with pathologically confirmed advanced or metastatic nonsquamous NSCLC and specific EGFR exon 20 insertion mutations who have not received prior systemic treatment.
✕Probably not a fit
Patients with early-stage NSCLC or those who have received prior systemic treatment for their advanced disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the safety and efficacy of zipalertinib when combined with standard first-line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR exon 20 insertion mutations. It consists of two parts: a safety lead-in to determine the optimal dose of zipalertinib, followed by a randomized Phase 3 trial comparing the combination treatment to chemotherapy alone. Patients who progress on chemotherapy may have the option to receive zipalertinib as a monotherapy. The study will be conducted across multiple sites in Nevada.
Why it matters
Potential benefit: If successful, this treatment could provide a new effective option for patients with a specific mutation in advanced lung cancer.
How similar studies have gone: While this approach is novel for this specific mutation, similar studies have shown promise in targeting other mutations in lung cancer.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion- 1. Provide written informed consent. 2. ≥18 years of age (or meets the country's regulatory definition for legal adult age, whichever is greater). 3. Pathologically confirmed, locally advanced or metastatic nonsquamous NSCLC 4. Has not received any prior systemic treatment for their locally advanced or metastatic nonsquamous NSCLC. Prior adjuvant/neoadjuvant treatment received \>6 months prior to first dose of study treatment is allowed for early-stage NSCLC. Prior monotherapy with an approved EGFR TKI (ie, gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib) as nonstandard first-line therapy for the treatment of locally advanced or metastatic disease is allowed if all of the following criteria are met: 1. Treatment duration did not exceed 8 weeks; 2. Lack of disease response was documented (radiographically) by an increase in tumor burden (a copy of the computerized tomography \[CT\] report showing increase in tumor burden from baseline should be submitted); 3. Associated toxicities have resolved to baseline; and 4. The EGFR TKI was discontinued at least 2 weeks or 4 half-lives prior to randomization, whichever is longer. Prior therapy with EGFR TKI agents targeting exon20ins mutations including amivantamab, mobocertinib, sunvozertinib, furmonertinib, and poziotinib is not allowed. 5. Documented EGFR mutation status, as determined by local testing performed at a CLIA certified (US) or accredited (outside of the US) local laboratory, defined as follows: 1. Part A: EGFR ex20ins or other uncommon single or compound EGFR mutation 2. Part B: EGFR ex20ins mutation 6. Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFR mutation status and, where possible, other biomarkers. Patients with insufficient tissue (details provided in laboratory manual) may be eligible following discussion with the sponsor; a fresh biopsy will not be required. 7. Patients with brain metastasis(es) who have previously received definitive local treatment and have stable central nervous system (CNS) disease (defined as being neurologically stable and off corticosteroid for at least 2 weeks prior to enrollment) are eligible. If brain metastases are diagnosed on screening imaging, the patient may be rescreened for eligibility after definitive treatment. b. Asymptomatic brain metastases ≤2 cm in size can be eligible for inclusion if, in the opinion of the Investigator, immediate definitive treatment is not indicated. 8. At least one measurable lesion as determined per RECIST 1.1 for patients enrolling to Part B. Patients enrolling to Part A may be enrolled without measurable disease. 9. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 10. Adequate organ function, as defined by the laboratory value 11. Have a life expectancy of at least 3 months as assessed by the investigator. 12. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to administration of the first dose of study treatment. Female patients are not considered to be of childbearing potential if they are postmenopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy). 13. Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose and for 6 months after the last dose of study treatment or longer, based on local requirements. Exclusion - 1. Is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study. 2. Prior treatment with any of the following within the specific time frame specified: 1. Zipalertinib (TAS6417/CLN-081) at any time. 2. Thoracic radiotherapy ≤28 days, palliative radiation of nonthoracic disease ≤14 days, or palliative radiation of a single lesion ≤7 days prior to first dose of study treatment. 3. Major surgery (excluding placement of vascular access) ≤28 days prior to first dose of study treatment. 4. All prescribed medication, over-the-counter medication, vitamin preparations and other food supplements, or herbal medications that are strong or moderate CYP3A4 inducers or inhibitors within 7 days prior to first dose. 3. Have any unresolved toxicity of Grade ≥2 from previous anticancer treatment in the neoadjuvant or adjuvant setting, except for Grade 2 alopecia or skin pigmentation. Patients with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the investigator and Sponsor. 4. Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or any evidence of clinically active interstitial lung disease. 5. Impaired cardiac function or clinically significant cardiac disease, including any of the following: 1. History of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification . 2. Serious cardiac arrhythmias requiring treatment. 3. Resting corrected QT interval (QTc) \>470 msec calculated using Fridericia's formula (QTcF). 6. Unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal (GI) absorption of zipalertinib (such as inflammatory bowel disease, malabsorption syndrome, or prior GI resection). 7. History of another primary malignancy ≤2 years prior to the date of first dose of study treatment unless at least one of the following criteria are met: 1. Adequately treated basal or squamous cell carcinoma of the skin 2. Cancer of the breast or cervix in situ 3. Previously treated malignancy, if all treatment for that malignancy was completed at least 2 years prior to first dose of study treatment, and no current evidence of disease 4. Concurrent malignancy determined to be clinically stable and not requiring tumor directed treatment 8. Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is unstable or not controlled with treatment. 9. History of COVID-19 infection within 4 weeks prior to enrolment and/or have persistent, clinically significant pulmonary symptoms related to prior COVID-19 infection. 10. Active bleeding disorders. 11. Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in structure or class. To platinum-containing drugs (ie, cisplatin, carboplatin), pemetrexed, or any known excipients of these drugs. b. Contraindications toning drugs (ie, cisplatin, carboplatin) or pemetrexed according to the respective local labels. 12. History of leptomeningeal disease and spinal cord compression. 13. Is unable or unwilling to take dexamethasone, folic acid, and/or vitamin B12 supplementation during treatment with pemetrexed. 14. Is pregnant or lactating or planning to become pregnant 15. The patient is, in the investigator's opinion, unable or unwilling to comply with the trial procedures.
Where it's running
-
Comprehensive Cancer Centers of Nevada - Henderson
Henderson, Nevada, United States Recruiting -
Comprehensive Cancer Centers of Nevada - Horizon Ridge Henderson
Henderson, Nevada, United States Recruiting -
Comprehensive Cancer Centers of Nevada - Southeast Henderson - Stephanie
Henderson, Nevada, United States Recruiting -
Comprehensive Cancer Centers of Nevada - Summerlin Medical Center II
Las Vegas, Nevada, United States Recruiting -
Comprehensive Cancer Centers of Nevada - Southwest
Las Vegas, Nevada, United States Recruiting -
Comprehensive Cancer Centers of Nevada - Central Valley - Twain
Las Vegas, Nevada, United States Recruiting
Show 44 more locations
-
Comprehensive Cancer Centers of Nevada - Northwest
Las Vegas, Nevada, United States Recruiting -
Gabrail Cancer and Research Center
Canton, Ohio, United States Recruiting -
University of Texas MD Anderson Cancer Center
Houston, Texas, United States Recruiting -
Universitair Ziekenhuis Leuven - Campus Gasthuisberg
Leuven, Flemish Brabant, Belgium Recruiting -
Algemeen Ziekenhuis Maria Middelares
Gent, Oost-Vlaaderen, Belgium Recruiting -
Algemeen Ziekenhuis Delta - Campus Menen
Menen, West Flanders, Belgium Recruiting -
Algemeen Ziekenhuis Delta - Campus Rumbeke
Rosières, West-Vlaanderen, Belgium Recruiting -
Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil Recruiting -
Hospital São Lucas da PUCRS
Porto Alegre, Rio Grande Do Sul, Brazil Recruiting -
Clínica Neoplasias Litoral
Itajaí, Santa Catatina, Brazil Recruiting -
Hospital Amaral Carvalho
Jaú, São Paulo, Brazil Recruiting -
Multi-profile Hospital for Active Treatment Uni Hospital
Panagyurishte, Pazardzhik, Bulgaria Recruiting -
University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna-ISUL
Sofia, Bulgaria Recruiting -
William Osler Health System - Brampton Civic Hospital
Brampton, Ontario, Canada Recruiting -
Les Hôpitaux Universitaires de Strasbourg
Strasbourg cedex, Alsace, France Recruiting -
Hôpital Côte De Nacre
Caen cedex 9, Basse-Normandie, France Recruiting -
Institut Curie
Paris cedex, Ile-de-France, France Recruiting -
Centre Hospitalier Universitaire Limoges
Limoges, Limousin, France Recruiting -
Hôpital Haut-Lévêque
Pessac, Nouvelle-Aquitaine, France Recruiting -
Centre Hospitalier Le Mans
Le Mans cedex 9, Pays De La Loire, France Recruiting -
Gustave Roussy
Villejuif, Val-de-Marne, France Recruiting -
Hôpital Ambroise-Paré
Boulogne-Billancourt, Île-de-France, France Recruiting -
Asklepios Klinik Altona
Hamburg, Hamburg (Hansestadt), Germany Recruiting -
Universitätsklinikum Gießen und Marburg - Gießen
Gießen, Hessen, Germany Recruiting -
Universitätsklinikum Regensburg
Regensburg, Germany Recruiting -
General Hospital for Thoracic Diseases Sotiria
Athens, Attica, Greece Recruiting -
Metropolitan General
Piraeus, Attica, Greece Recruiting -
University General Hospital of Patras
Patra, Peloponnese, Greece Recruiting -
Metropolitan Hospital
Peiraias, Pireas, Greece Recruiting -
University General Hospital of Larissa
Larissa, Thessaly, Greece Recruiting -
BioClinic Thessaloniki
Thessaloniki, Greece Recruiting -
Emek Medical Center
Afula, Israel Recruiting -
Shaare Zedek Medical Center
Jerusalem, Israel Recruiting -
Hadassah University Hospital Ein Kerem
Jerusalem, Israel Recruiting -
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel Recruiting -
Assuta Hospital - Ramat HaHayal
Tel aviv, Israel Recruiting -
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST
Meldola, Forlì-Cesena, Italy Recruiting -
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele
Milan, Italy Recruiting -
Azienda Ospedaliero - Universitaria di Modena
Modena, Italy Recruiting -
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy Recruiting -
Azienda Unità Sanitaria Locale della Romagna
Ravenna, Italy Recruiting -
Azienda Ospedaliera Universitaria Integrata Verona
Verona, Italy Recruiting -
Aichi Cancer Center
Nagoya, Aiti [Aichi], Japan Recruiting -
Hirosaki University Hospital
Hirosaki-Shi, Aomori, Japan Recruiting
+64 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: Taiho Oncology, INC
- Email: medicalinformation@taihooncology.com
- Phone: +1 844-878-2446
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Zipalertinib vs placebo after surgery for uncommon EGFR-mutant NSCLC
This study tests whether zipalertinib can help people with early-stage, surgically removed NSCLC that has uncommon EGFR mutations-by comparing it to placebo.
-
Evaluating zipalertinib for advanced lung cancer with specific EGFR mutations
This study is testing a new drug called zipalertinib to see if it can help people with advanced lung cancer that has specific genetic mutations and who have few other treatment options.
-
Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer
This study will try giving amivantamab together with platinum chemotherapy to adults with metastatic NSCLC who have specific EGFR mutations to see how long their cancer stays controlled and how safe the treatment is.
-
BEBT-109 treatment for lung cancer with specific mutations
This study is testing a new drug called BEBT-109 to see if it can help people with a specific type of lung cancer that has certain mutations, especially those who haven't had much success with other treatments.
-
Understanding resistance to amivantamab in lung cancer patients
This study is trying to understand why some lung cancer patients with a specific mutation stop responding to the drug amivantamab, by looking at their blood and tumor samples after their disease gets worse.
-
Assessing furmonertinib for lung cancer patients with specific mutations after surgery
This study is testing if a new drug called furmonertinib can help lung cancer patients with specific mutations stay cancer-free after their surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.